Product Type
Fc Silent Antibody
Description
The antibody Fc domain is responsible for the function in the antibody, while the Fab domain is responsible for targeting. Therefore, Fc engineering represents the engineering function of antibodies, which are effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), and control the serum half-life. Therefore, Fc engineering for immune silencing or further protein engineering is essential for immune cell binding to antibodies.
The Fc-silenced antibody provided by Creative Biolabs contains key point mutations that eliminate the binding of Fc receptors (FcγR, FcR), thereby eliminating the cytotoxic (ADCC) effector function of the antibody.
Species
Human
Clonality
Monoclonal
Conjugation
Unconjugated
Source
Recombinant
Buffer
PBS, pH 7.4
Application
Funcs, In vivo assay
Application Notes
The use of diluent depends on the detection system used. It is recommended that users test reagents and determine their own optimal dilution.
Storage Instructions
Product should be stored at -20°C. Repeated freeze and thaw cycles will cause loss of activity. Use product within 24 hours after thawing and keep on ice. Remainder amounts should be aliquoted and immediately re-freezed for future use. Aliquots should never be thawed more than once. Under recommended storage conditions, product is stable for at least one year.
Official Name
ERBB2
Full Name
erb-b2 receptor tyrosine kinase 2
Background
This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
Alternative Names
NEU; NGL; HER2; TKR1; CD340; HER-2; MLN 19; HER-2/neu
Gene ID
2064
Uniprot ID
P04626
